AgomAb Therapeutics N.V. American Depositary Shares
AGMB
Get informed when a big investor buys or sells
+ FollowMarket Cap$633.82M
Close$
$35.00
172% upsideAgomAb Therapeutics N.V. American Depositary Shares Target Price Details
Target Price by Analysts
172% upsideAgomAb Therapeutics N.V. American Depositary Shares Target Price Details$2.00
84.4% downside
Current Fair Value
84.4% downsideOvervalued by 84.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $633.82 Million |
|---|---|
| Enterprise Value | $550.38 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.23 |
| Beta | 1.73 |
| Outstanding Shares | 48,736,779 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -9.07 |
|---|---|
| PEG | -18.77 |
| Price to Sales | - |
| Price to Book Ratio | 6.44 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.92%▲ 47.92% |
|---|---|
| Total Invested | $245.30M |
| Investors Holding | 32▲ 32.00% |
ESG Score
No data
About AgomAb Therapeutics N.V. American Depositary Shares
57 employees
CEO: Tim Knotnerus AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's ...